Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFUL.L Regulatory News (FUL)

  • There is currently no data for FUL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EPT Disclosure

24 Mar 2010 09:35

RNS Number : 0889J
Seymour Pierce Ltd
24 March 2010
 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

WITH RECOGNISED INTERMEDIARY STATUS

DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(a) of the Takeover Code)

 

1. KEY INFORMATION

 

Name of exempt principal trader

Seymour Pierce Limited

Company dealt in

Fulcrum Pharma plc

Class of relevant security to which the dealings being disclosed relate (Note 1)

Ordinary 1p Shares

Date of dealing

23.03.10

 

 

2. DEALINGS (Note 2)

 

(a) Purchases and sales

 

Total number of securities purchased

 

Highest price paid (Note 3)

Lowest price paid (Note 3)

40,000

0.02560 GBP

0.02560 GBP

 

 

Total number of securities sold

 

Highest price received (Note 3)

Lowest price received (Note 3)

108,000

0.02780 GBP

0.02780 GBP

 

(b) Derivatives transactions (other than options)

 

Product name,

e.g. CFD

Long/short (Note 4)

Number of securities (Note 5)

Price per unit (Note 3)

 

 

 

 

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

 

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 5)

Exercise

price

Type, e.g. American, European etc.

Expiry

date

Option money

paid/received per unit (Note 3)

 

(ii) Exercising

 

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 3)

 

 

 

 

 

3. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

Date of disclosure

24.03.10

Contact name

Caroline Woodyer

Telephone number

020 7107 8056

Name of offeree/offeror with which connected

Fulcrum Pharma plc

Nature of connection (Note 6)

Nomad and Broker

 

 

Notes

 

The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMKKQDNCBKKPNB
Date   Source Headline
11th Apr 202312:00 pmRNSForm 8.5 (EPT/RI)
11th Apr 202312:00 pmRNSForm 8.5 (EPT/RI) - The Fulham Shore Plc
11th Apr 202310:20 amRNSForm 8.3 - The Fulham Shore PLC
6th Apr 20233:57 pmRNSForm 8.3 - Fulham Shore Plc
6th Apr 202312:13 pmGNWForm 8.3 - [The Fulham Shore plc - Opening Declaration - 05 04 2026] - (CGAML)
6th Apr 202312:00 pmRNSForm 8.5 (EPT/RI) - The Fulham Shore Plc
6th Apr 202310:43 amRNSForm 8.5 (EPT/RI)
5th Apr 20234:51 pmRNSForm 8.3 - The Fulham Shore plc
5th Apr 20232:40 pmRNSForm 8.3 - Fulham Shore Plc
5th Apr 202312:47 pmRNSForm 8.3 - The Fulham Shore PLC
5th Apr 202312:43 pmRNSForm 8.3 - FULHAM SHORE PLC/THE
5th Apr 202311:10 amBUSForm 8.3 - The Fulham Shore PLC
5th Apr 20237:30 amRNSRecommended Offer for The Fulham Shore PLC
5th Apr 20237:30 amRNSTrading Update
29th Mar 20237:00 amRNSExercise of options and total voting rights
10th Mar 20233:35 pmRNSHolding(s) in Company
3rd Jan 20234:10 pmEQSHardman & Co Research on The Fulham Shore (FUL): Resilient first-half trading
16th Dec 20229:05 amRNSSecond Price Monitoring Extn
16th Dec 20229:00 amRNSPrice Monitoring Extension
16th Dec 20227:00 amRNSHalf-year Report
7th Dec 202211:05 amRNSSecond Price Monitoring Extn
7th Dec 202211:00 amRNSPrice Monitoring Extension
2nd Dec 20224:29 pmRNSHolding(s) in Company
1st Nov 20227:00 amRNSBusiness Development & Trading Update
31st Aug 20224:23 pmRNSResult of AGM
31st Aug 20227:00 amRNSAGM Statement & Trading Update
23rd Aug 202210:10 amEQSHardman & Co Interview on: The Fulham Shore Plc (FUL) Full ahead
9th Aug 20229:30 amRNSPublication of Annual Report & Notice of AGM
1st Aug 202212:32 pmEQSHardman & Co Research: The Fulham Shore (Initiation of coverage): Platform ready for take-off
21st Jul 20227:00 amRNSFinal Results
8th Jun 20227:00 amRNSTrading Update and Notice of Final Results
4th Apr 20227:00 amRNSTrading Update
21st Jan 202212:00 pmRNSExercise of Options & Total Voting Rights
18th Jan 20226:10 pmRNSExercise of Options & Total Voting Rights
13th Jan 20225:38 pmRNSHolding(s) in Company
13th Jan 202212:30 pmRNSExercise of Options and Total Voting Rights
11th Jan 202212:45 pmRNSExercise of Options and Total Voting Rights
7th Jan 20225:27 pmRNSExercise of Options and Total Voting Rights
29th Dec 20218:43 amRNSPDMR Dealing
6th Dec 202112:05 pmEQSHardman & Co Research: The Fulham Shore (FUL) - Investor Forum company research (Nov 2021)
6th Dec 20217:00 amRNSHalf-year Report
2nd Dec 20211:00 pmRNSNotice of Interim Results
1st Dec 20217:00 amRNSTotal Voting Rights
8th Nov 20214:50 pmRNSChange of Registrar
8th Nov 20212:18 pmEQSHardman & Co Research : Hardman & Co Video Event | The Fulham Shore plc - Investor Forum
5th Nov 20216:08 pmRNSExercise of Options and Total Voting Rights
4th Nov 20217:00 amRNSTrading Update
3rd Nov 20214:40 pmEQSHardman & Co Video Event | The Fulham Shore plc Investor Forum
29th Oct 20214:30 pmRNSTotal Voting Rights
7th Oct 20215:18 pmRNSExercise of Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.